- #TYME STOCK NEWS FOR FREE#
- #TYME STOCK NEWS TRIAL#
The Company is also conducting a comprehensive translational preclinical program focused on SM-88 MOA and Biomarker Identification/Validation and has engaged Evotec SE (NASDAQ: EVO) to aid in executing these activities. Next month, a poster presentation from the Phase 2 OASIS study of SM-88 in HR+/HER2- breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting. TYME continues to evaluate SM-88 in two separate Phase 2 investigator-sponsored studies in HR+/HER2- breast cancer and sarcoma.
With $92 million in cash and marketable securities as of December 31, 2021, we believe that TYME is in a strong position to find an advantageous transaction," stated Richie Cunningham, Chief Executive Officer of TYME. "The goal of the strategic evaluation process is to ensure that we are exploring a range of possible options to maximize value for our stockholders. (NASDAQ:TYME), David Carberry, Just Bought 100 More Shares Tyme Technologies, Inc. The Company does not intend to disclose additional details unless and until entered into a specific transaction. TYME News Headlines The Independent Director of Tyme Technologies, Inc. The Board's Strategic Planning Committee will act as a Transaction Committee and be led by TYME Board Member Timothy C.
#TYME STOCK NEWS TRIAL#
In January, TYME announced the discontinuation of a randomized Phase II/III trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for metastatic pancreatic cancer upon learning that the trial sponsor terminated the study arm due to futility. It has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor. Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME's expected net cash at closing and TYME.
#TYME STOCK NEWS FOR FREE#
A spokesperson for the Centers for Medicare and Medicaid Services said that, once the public health emergency ends, “some Medicare Advantage plans may cover and pay for COVID-19 tests as an added benefit.” People who are covered under Medicaid or the Children’s Health Insurance Program will be eligible for free tests through September 2024.TYME Technologies Inc (NASDAQ: TYME) has decided to explore potential strategic options. For people outside of California, “coverage depends on state or local mandates in-network and out-of-network coverage for COVID-19 vaccines, testing, and treatment,” a Kaiser Permanente representative said in a statement. 11, 2023 to members in that state, except those covered under Medicare Advantage plans. Kaiser Permanente, which is based in California, will provide up to eight free tests per month through Nov. After that, Blue Cross Blue Shield plans may implement “reasonable limits on the use of tests.” Local chapters that make up the national Blue Cross Blue Shield Association will reimburse at-home testing costs through May 11, confirmed executive vice president and chief corporate affairs officer Sean Robbins in a statement provided to TIME. A representative from Aetna declined to comment, but information posted online says it will not cover at-home tests beginning May 12. A representative from UnitedHealthcare did not provide a comment before press time, but its website specifies that over-the-counter tests will not be covered after May 11 “unless mandated by state regulatory requirements.” California state law, for example, extends the free testing provision through Nov. However, information posted on Cigna’s website says it will no longer cover at-home tests starting May 12, 2023. A representative from Cigna did not respond to TIME’s comment requests by press time. Here’s how some major insurers are planning to handle the end of the public health emergency: LOS ANGELES, /PRNewswire/ - Sybersound, a record company based in Malibu, CA and distributed by Universal Music Group, is proud to announce that the Party Tyme Karaoke En Español.
0 kommentar(er)
